You are here: Home » News-ANI » Health
Business Standard

Testosterone slows prostate cancer recurrence in low-risk patients

ANI 

US researchers have found out that replacement slows the recurrence of in low-risk patients.

One of the largest studies undertaken so far may call into question the general applicability of Nobel-Prize winning hormonal treatment. The work was presented at the congress in

Doctors have long regarded as a hormone which promotes The 1941 work of Huggins and Hodges won Huggins the 1966 Nobel Prize for Medicine, for reporting the dramatic impact of reduction on Since then, medicines which reduce levels of the hormone testosterone have become a standard option for many patients.

However, in the late 1990s to 2000s, doctors discovered that although men on long term anti-testosterone treatments were not dying from prostate cancer, they were dying prematurely of cardiovascular It seemed that although anti-testosterone therapies were treating the prostate cancer, the extremely low testosterone levels were significantly worsening metabolic complications such as elevated blood sugar, diabetes, elevated cholesterol, mid-abdomen visceral fat, etc. Low testosterone also caused a loss of sexual function in many men on anti-androgen treatment. This led some doctors to suggest testosterone treatment of some low-risk men after or

Starting in 2008, a team of doctors from the University of California, Irvine, led by Thomas Ahlering, began to carefully select patients for after primary with robotic radical in a bid to improve recovery of sexual function.

The team worked with 834 patients undergoing radical They treated 152 low-risk patients with no evidence of with therapy. After a median of 3.1 years following surgery, they tested the patients for biochemical recurrence of cancer, as indicated by measurement of the Prostate Specific Antigen (PSA) levels. They found that cancer had recurred in only approximately 5% of treated patients, whereas cancer had recurred in 15 per cent of the patients who did not receive testosterone. Overall, after accounting for differences between the groups, they found nearly a three-fold reduction by three years.

commented "This is not what we set out to prove, so it was a big surprise: not only did not increase recurrence, but it actually lowered recurrence rates. While the testosterone is not curing cancer per se, it is slowing the growth of cancer, giving an average of an extra 1.5 years before traces of cancer can be found. We already know that testosterone can help with physiological markers such as muscle mass, better cholesterol and triglyceride levels and increased sexual activity, so this seems to be a win-win".

"There have been smaller studies which have hinted that testosterone may not be risky for certain patient groups, but this is the largest such study ever conducted. We're not suggesting that treatment methods be changed just yet, but this puts us at the stage where we need to question the taboo against testosterone use in - especially for low-risk patients after radical We need the oncology/urology community to begin to review testosterone use," he added.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Sun, March 17 2019. 16:17 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU